MedTrace Logo

Bexarotene With Narrow-Band UVB for Psoriasis

NCT00151008 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2008-08-07

No results posted yet for this study

Summary

To determine if bexarotene gel with NBUVB phototherapy is more effective than placebo plus NBUVB for moderate to severe plaque-type psoriasis.

Conditions

Interventions

DRUG

Bexarotene/NBUVB vs placebo NBUVB

Sponsors & Collaborators

  • Ligand Pharmaceuticals

    collaborator INDUSTRY

  • University of Medicine and Dentistry of New Jersey

    lead OTHER

Principal Investigators

  • Melissa Magliocco, MD · Rutgers, The State University of New Jersey

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Completion
2005-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00151008 on ClinicalTrials.gov